CHF96.17
0.75%
SIX Swiss Exchange, Jun 28, 05:30 pm CET
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Novartis Share price

CHF96.17
+5.06 5.55% 1M
+12.13 14.43% 6M
+11.30 13.31% YTD
+13.32 16.08% 1Y
+16.71 21.03% 3Y
+12.69 15.21% 5Y
+29.74 44.77% 10Y
SIX Swiss Exchange, Closing price Fri, Jun 28 2024
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Key figures

Market capitalization CHF188.16b
Enterprise Value CHF204.02b
PER (TTM) P/E ratio 14.63
EV/FCF (TTM) EV/FCF 18.05
EV/Sales (TTM) EV/Sales 4.73
P/S ratio (TTM) P/S ratio 4.36
P/B ratio (TTM) P/B ratio 5.49
Dividend yield 3.43%
Last dividend (FY23) CHF3.30
Sales growth (TTM) Sales growth -11.40%
Turnover (TTM) Turnover CHF43.13b
EBIT (operating result TTM) EBIT CHF11.81b
Free cash flow (TTM) Free cash flow CHF11.31b
Cash position CHF8.78b
EPS (TTM) EPS CHF6.57
P/E ratio expected 20.01
P/S ratio expected 4.25
EV/Sales expected 4.60
Show more

Register now for free to activate an alarm for the Novartis share.

Activate alerts on the share price, dividend yield, valuation (e.g. P/E ratio or EV/sales) or strategy scores and sit back and relax.

Novartis Share analysis

Analyst opinions

29 Analysts have issued a Novartis forecast:

10x Buy
34%
17x Hold
59%
2x Sell
7%

Analyst opinions

29 Analysts have issued a Novartis forecast:

Buy
34%
Hold
59%
Sell
7%

Financial data from Novartis

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
43,132 43,132
11% 11%
100%
- Direct costs 12,024 12,024
19% 19%
28%
31,108 31,108
8% 8%
72%
- Selling and administrative expenses 4,636 4,636
23% 23%
11%
- Research and development costs 7,716 7,716
8% 8%
18%
18,755 18,755
4% 4%
43%
- Depreciation and amortization 6,947 6,947
6% 6%
16%
EBIT (operating result) EBIT 11,808 11,808
2% 2%
27%
Net profit 13,512 13,512
102% 102%
31%

Figures in millions CHF.

Don't miss a thing! We will send you all news about the Novartis share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Novartis Share News

marktEINBLICKE
4 months ago
Nach einigen Abspaltungen gehört die Übernahme des deutschen Biotechnologieunternehmens MorphoSys zur neuen Strategie bei Novartis.
marktEINBLICKE
5 months ago
Während sich Anleger mit der geplanten Übernahme von MorphoSys durch Novartis befassen, bewegte sich der DAX auf ein neues Rekordhoch.
marktEINBLICKE
5 months ago
Der Schweizer Pharmakonzern Novartis schnappt sich MorphoSys. Nicht nur für die Aktionäre des deutschen Biotech-Unternehmens lohnt sich der Deal.
More Novartis News

Company profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 76,057
Founded 1996
Website www.novartis.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now